Alluvi, formerly BI 4744, offers a significant development in obesity therapy. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates impressive efficacy in https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/